3-Methylamino-4-{2-[(pyridin-2-yl)methylthio]ethylamino}-1,2,5-thiadiazole 1,1-dioxide | 78441-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Methylamino-4-{2-[(pyridin-2-yl)methylthio]ethylamino}-1,2,5-thiadiazole 1,1-dioxide
• 英文别名: 3-Methylamino-4-{2-[(2-pyridyl)methylthio]ethylamino}-1,2,5-thiadiazole 1,1-dioxide；4-N-methyl-1,1-dioxo-3-N-[2-(pyridin-2-ylmethylsulfanyl)ethyl]-1,2,5-thiadiazolidine-3,4-diimine
• CAS: 78441-73-3
• 化学式: C₁₁H₁₅N₅O₂S₂
• 分子量: 313.404
• InChiKey: FJPRWGOZUPFETO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  130
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[(2-aminoethyl)thiomethyl]pyridine 以 甲醇 为溶剂， 反应 3.0h， 生成 3-Methylamino-4-{2-[(pyridin-2-yl)methylthio]ethylamino}-1,2,5-thiadiazole 1,1-dioxide
  参考文献：
  名称：

  Pyridine and reduced pyridine analogues of 1,2,5-thiadiazoles as histamine H2-receptor antagonists

  摘要：

  DOI：

  10.1016/0223-5234(87)90269-8

文献信息

• Chemical compounds
  申请人：Bristol-Myers Company

  公开号：US04394508A1

  公开（公告）日：1983-07-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组胺H.sub.2-拮抗剂的化学结构为##STR1##，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的5至9成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性的药学可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。揭示了其中间体和制备方法。
• Histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04510309A1

  公开（公告）日：1985-04-09

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮杂环环的5到9成员完全饱和的环；m为0到2的整数，n为2到4的整数；Z为硫、氧或亚甲基；A为可选取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性药用可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。公开了其制备的中间体和方法。
• AGRAWAL, VIJAI K.;KNAUS, EDWARD E.;MCNEILL, JOHN H., EUR. J. MED. CHEM., 22,(1987) N 4, 319-323
  作者：AGRAWAL, VIJAI K.、KNAUS, EDWARD E.、MCNEILL, JOHN H.

  DOI：——

  日期：——
• Pharmaceutical compositions
  申请人：Bristol-Myers Company

  公开号：EP0099121B1

  公开（公告）日：1989-10-25
• US4374248A
  申请人：——

  公开号：US4374248A

  公开（公告）日：1983-02-15